News & Blogs
The latest news and thinking about migraine
Filter by...
-
NICE approves Rimegepant for acute use on the NHS in England
Rimegepant is now approved for acute and preventative treatment of migraine on the NHS in England
Read more about this
-
Rimegepant approved for preventative use in Scotland
Rimegepant approved for use in NHS Scotland for the acute and preventative treatment of migraine
Read more about this
-
Migraine Awareness Week 2023
Join our call for better migraine care this Migraine Awareness Week (24-30 September)
Read more about this
-
Research reveals that over a third of people have experienced discrimination at work because of their migraines
Research reveals extent of workplace discrimination due to migraine
Read more about this
-
NICE approves migraine medication Rimegepant for preventive use on the NHS in England
Unfortunately it has not been approved for acute use
Read more about this
-
The Migraine Trust Fellowship recipients announced
Neuroscientists awarded fellowships for projects that seek to learn more about the role of hormones in migraine
Read more about this
-
We welcome the decision by SMC to approve migraine medication Rimegepant for use in NHS Scotland
Approved for the acute treatment of migraine
Read more about this
-
Migraine News: Issue 126
Read the latest edition of our magazine, Migraine News
Read more about this
-
NICE has rejected migraine medication Rimegepant for use on the NHS in England
We are very concerned about the unnecessary suffering of people with medication overuse headache and those without effective treatment for their migraine
Read more about this
-
The SMC approves eptinezumab (Vyepti) to treat episodic and chronic migraine
This follows last month’s NICE approval of it
Read more about this
-
We welcome the new clinical care pathway for the UK’s 10 million people with migraine
It now needs to be urgently implemented
Read more about this
-
NICE approves eptinezumab (Vyepti) to treat episodic and chronic migraine
Eligible patients must have access
Read more about this
